Navigation Links
Mylan Restores Availability of Generic Levothyroxine in Florida
Date:2/8/2008

PITTSBURGH, Feb. 8 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has obtained an order from an administrative law judge in Florida finding that the inclusion of Levothyroxine Sodium on the state's negative drug formulary is an invalid exercise of legislative authority and that the product should be removed from the negative formulary.

Mylan will make its products available to pharmacies in Florida as soon as motions and procedural steps surrounding its removal from the negative formulary are satisfied. Florida's Board of Medicine and Board of Pharmacy voted not to appeal the Jan. 28, 2008, order; Abbott Laboratories has filed a formal appeal.

When a drug is included on Florida's negative formulary, pharmacists cannot substitute a generic version for a prescribed brand version. Florida pharmacists have been prohibited from substituting the generic version of Levothyroxine Sodium, depriving patients access to an affordable, effective and safe generic approved by the U.S. Food and Drug Administration.

In August 2007, Mylan filed a petition against Florida's Department of Health, Board of Pharmacy and Board of Medicine challenging the validity of Levothyroxine's inclusion on the negative formulary. Abbott Laboratories, maker of a brand version of Levothyroxine Sodium (Synthroid(R)), intervened. In an order issued Jan. 28, Mylan's subsequent motion for summary final order was granted.

"This ruling is not just a victory for Mylan, it's a major victory for the citizens of Florida who have been denied access to lower cost Levothyroxine Sodium for years," said Mylan's Chief Operating Officer Heather Bresch. "The state will benefit from tens of millions of dollars in savings as a result of this decision, and we are extremely pleased that the judge on this case saw through the brand company's baseless tactics to limit consumer access to affordable and effective medications."

Levothyroxine Sodium is indicated for the treatment of hypothyroidism and pituitary TSH suppression. According to IMS Health, more prescriptions are filled nationwide with Mylan's Levothyroxine Sodium tablets than any other Levothyroxine product, brand or generic. Mylan's version is the only generic product considered therapeutically equivalent to four brand versions, including Synthroid(R), Levoxyl(R), Levothroid(R) and Unithroid(R).

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it ... to couches to dressers and bicycles. Roadie — the national on-the-way delivery network — ... center through February 28th. , “January is an exciting time when resolutions are ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out ... trade show to continue the marketing and distribution of its product, The Right C. ... 400 percent better absorption than traditional vitamin C supplements. At the trade show, Doctor ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, ... ... creating nutritional and wellness products to enhance people’s everyday lives, recently attended the ... major retail buyers. , ATP Science is known for its large range of ...
(Date:1/20/2017)... ... 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that ... Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains ... lens flare and light leak transitions have a very high-dynamic range for super smooth ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming ... set out for each of his children. “The Angel” is the creation of published ... in New York City, and impassioned writer. , When asked of her new book, ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan 20, 2017 Research ... Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic ... report to their offering. ... Global Hearing Aids Market Sales Volume, Company ... the fast-evolving, high-growth hearing aid industry. The growing ...
(Date:1/20/2017)... DUBLIN , Jan 20, 2017 ... Pharmaceutical Stability Testing Market Trends, Opportunities, and Future" report to ... ... market sizing, emerging trends, and technologies, and provides a snapshot of ... year is 2015 and forecasts are provided from 2016 to 2020. ...
(Date:1/20/2017)... -- Entscheidung fällt als Reaktion ... Die internationale humanitäre Stadt soll um knapp 2800 m² erweitert ... Seine Hoheit Scheich Muhammad bin Raschid Al ... Dubai , hat den Auftrag erteilt, ... City IHC) zu verdreifachen, um den Betrieb zur Unterstützung ...
Breaking Medicine Technology: